SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form C - Offering Statement:
SEC Accession No. 0001669191-22-000053
Filing Date
2022-01-19
Accepted
2022-01-19 11:18:08
Documents
8

Document Format Files

Seq Description Document Type Size
1 primary_doc.html C  
1 primary_doc.xml C 10707
2 OFFERING STATEMENT PDF offeringstatement.pdf EX-99 129864
3 OFFERING PAGE JPG offeringpage.jpg GRAPHIC 71620
4 CPA REVIEW REPORT reviewletter.pdf EX-99 447968
5 CERTIFICATE OF INCORPORATION certificateofincorporation.pdf EX-99 79313
6 CORPORATE BYLAWS corporatebylaws.pdf EX-99 88080
7 ADDITIONAL INFORMATION otherfinancial.pdf EX-99 157305
8 IMAGE ATTACHMENTS HTML imageattachments.htm EX-99 244
  Complete submission text file 0001669191-22-000053.txt   1354060
Mailing Address 329 OYSTER POINT BLVD., 3RD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 329 OYSTER POINT BLVD., 3RD FLOOR SOUTH SAN FRANCISCO CA 94080 408.809.1030
BioEclipse Therapeutics, Inc. (Filer) CIK: 0001780708 (see all company filings)

IRS No.: 320304849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: C | Act: 33 | File No.: 020-29552 | Film No.: 22537368